



FOR IMMEDIATE RELEASE

TSX Venture Exchange: MDX

MedX receives Corporate Citizenship Award from the Melanoma Network of Canada

MISSISSAUGA, ON, February 13, 2018 – MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that it received a Corporate Citizenship Award from the Melanoma Network of Canada (“MNC”) for MedX’s work in raising melanoma awareness.

Alexa Cain, Executive Director of MNC, and Don Fernald, a Director on MNC’s Board, presented a plaque and a glass sculpture, designed by acclaimed Canadian artist Paull Rodrigue, to the MedX team at MedX’s offices in Mississauga.

“The support from MedX has been truly amazing and inspiring. MedX has helped champion the work we do at MNC, and is our partner in providing information about early skin cancer detection, providing skin screening at our charity events,” Ms. Cain said.

Accepting the award on behalf of MedX, Mr. von der Porten said, “It is an honor for MedX to be acknowledged by the MNC. We believe in the great work they do in helping individuals and their families afflicted by melanoma and other skin cancers. We also believe that MedX’s pain-free SIAscopy technology is a game-changer for the early detection of skin cancers. Our goal is to significantly cut skin cancer mortality rates globally.”



(From Left) Don Fernald and Alexa Cain of the Melanoma Network of Canada, present a Citizenship award to MedX’s Robert von der Porten, Mike Druhan and Louie Canitano for MedX’s work in raising melanoma awareness.

Photo credit: Jane Axford, Melanoma Network of Canada

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

About Melanoma Network of Canada

The Melanoma Network of Canada (MNC) provides support services, information and programs for individuals whose lives have been changed by melanoma. MNC provides the leading national voice for melanoma patients in Canada for early detection and improved treatment access and works diligently to prevent more Canadians from developing melanoma through public awareness and youth and adult education on sun safety. For more information, please visit www.melanomanetwork.ca. Charitable Registration number: 854913050RR0001

Contacts:

Rob von der Porten, President & CEO

MedX Health Corp

905-670-4428 ext 226

Media Relations

Deborah Thompson

dthompson@medxhealth.com

416-918-9551